Chapter 1. Research Framework
1.1 Research Objective
1.2 Product Overview
1.3 Market Segmentation
Chapter 2. Research Methodology
2.1 Qualitative Research
2.1.1 Primary & Secondary Sources
2.2 Quantitative Research
2.2.1 Primary & Secondary Sources
2.3 Breakdown of Primary Research Respondents, By Region
2.4 Assumption for the Study
2.5 Market Size Estimation
2.6. Data Triangulation
Chapter 3. Executive Summary: Chemotherapy-Induced Peripheral Neuropathy Market
3.1. Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2020
3.2. Market Share (%) Distribution of Chemotherapy-Induced Peripheral Neuropathy in 2030
Chapter 4. Chemotherapy-Induced Peripheral Neuropathy Market Overview
4.1. Market Dynamics: Chemotherapy-Induced Peripheral Neuropathy Market
4.1.1. Drivers
4.1.1.1. Increase Emerging Therapies
4.1.1.2. Increasing awareness
4.1.2. Restraint
4.1.2.1. No standard assessment
4.1.2.2. Current therapy limitations
4.1.3. Opportunity
4.2. Porters Five Forces Analysis: Chemotherapy-Induced Peripheral Neuropathy
4.2.1. Bargaining Power of Suppliers
4.2.2. Bargaining Power of Buyers
4.2.3. Threat of Substitutes
4.2.4. Threat of New Entrants
4.2.5. Degree of Competition
4.3. Disease Background and Overview
4.3.1. Introduction
4.3.2. Sign and Symptoms
4.3.3. Pathophysiology
4.3.4. Risk Factors
4.3.5. Diagnosis
4.4. Competitive Intelligence Analysis for Chemotherapy-induced peripheral neuropathy
Chapter 5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3. Country Wise-Epidemiology of Chemotherapy-Induced Peripheral Neuropathy
5.3.1. United States
5.3.1.1. Prevalent cases of Chemotherapy-Induced Peripheral Neuropathy in the United States
5.3.1.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.1.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.2. EU5
5.3.2.a. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy in EU5
5.3.2.1. UK
5.3.2.1.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.2.1.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.2.1.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.2.2. France
5.3.2.2.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.2.2.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.2.2.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.3. Germany
5.3.3.3.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.3.3.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.3.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.4. Spain
5.3.3.4.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.3.4.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.4.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.5. Italy
5.3.3.5.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.3.5.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.5.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3. Japan
5.3.3.1. Prevalent Population of Chemotherapy-Induced Peripheral Neuropathy
5.3.3.2. Gender-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
5.3.3.3. Age-specific Chemotherapy-Induced Peripheral Neuropathy Prevalence
Chapter 6. Current Treatment Practices
6.1. Clinical Practice Guideline: Treatment of Chemotherapy-Induced Peripheral Neuropathy
6.2. Patient Journey
Chapter 7. Unmet Needs
Chapter 8. KOL's Views: Chemotherapy-Induced Peripheral Neuropathy
Chapter 9. Case Reports
Chapter 10. Marketed Products
10.1. List of Marketed Products in the 7MM
10.2. Olesoxime (TRO19622): MedImmune /Abbott Laboratories Inc.
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Other Developmental Activities
10.1.4. Pivotal Clinical Trials
10.1.5. Summary of Pivotal Clinical Trial
10.3. Calmangafodipir: Egetis Therapeutics /Solasia Pharma K.K.
10.4. Pregabalin: Pfizer's
Chapter 11. Emerging Therapies
11.1. Key Cross Competition
11.1.1. Thrombomodulin alfa: Veloxis Pharmaceuticals
11.1.2. Tetrodotoxin (TTX): Wex Pharmaceuticals
11.1.3. Sodium selenite pentahydrate: Boryung Pharmaceutical Co., Ltd
11.1.4. Memantine: Mendel AI
11.1.5. Nicotinamide Riboside: ChromaDex, Inc.
11.1.1.1. Drug Description
11.1.1.2. Clinical Development
11.1.1.3. Clinical Trials Information
11.1.1.4. Safety and Efficacy
11.1.1.5. Product Profile
11.1.1.6. Regulatory Milestones
11.1.2. TTX: WEX Pharmaceuticals
11.1.2.1. Drug Description
11.1.2.2. Clinical Development
11.1.2.3. Clinical Trials Information
11.1.2.4. Safety and Efficacy
11.1.2.5. Product Profile
11.1.2.6. Regulatory Milestones
11.1.3. Nicotinamide Riboside: ChromaDex, Inc.
11.1.3.1. Drug Description
11.1.3.2. Clinical Development
11.1.3.3. Clinical Trials Information
11.1.3.4. Safety and Efficacy
11.1.3.5. Product Profile
11.1.3.6. Regulatory Milestones
List to be continued in report
Chapter 12. Chemotherapy-Induced Peripheral Neuropathy: Market Analysis
12.1. Key Findings
12.2. Total Market Size of Chemotherapy-Induced Peripheral Neuropathy in the 7MM
12.3. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in the 7MM
Chapter 13. Market Size of Chemotherapy-Induced Peripheral Neuropathy by Country
13.1. United States Market Analysis
13.1.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in the US
13.1.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in the US
13.2. EU5 Market Outlook
13.2.1. United Kingdom
13.2.1.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in the UK
13.2.1.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in the UK
13.2.2. France
13.2.2.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in France
13.2.2.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in France
13.2.3. Germany
13.2.3.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in Germany
13.2.3.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in Germany
13.2.4. Spain
13.2.4.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in Spain
13.2.4.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in Spain
13.2.5. Italy
13.2.5.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in Italy
13.2.5.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in Italy
13.2.6. Japan
13.2.6.1. Market Size of Chemotherapy-Induced Peripheral Neuropathy in Japan
13.2.6.2. Therapy Based Market Size of Chemotherapy-Induced Peripheral Neuropathy in Japan
Chapter 14. Access and Reimbursement Overview of Chemotherapy-induced peripheral neuropathy
Chapter 15. ASTUTE Analytica Capabilities
Chapter 16. Disclaimer
Chapter 17. About ASTUTE Analytica